CD8A and neoplasm: The mechanism of action study found that disumab not only inhibited osteoblast activation but also significantly reduced serum OPN levels (an average decrease of 68% after treatment), while increasing the proportion of CD8 + TCF1 + Tpex cells in the tumor (from 3.2% at baseline to 9.8%).